Drug intelligence / Profile preview

KNP-502

Development stage: Phase 1
Lead developer: Oscotec
Modality: Small Molecules

Overview

KNP-502 is a small molecule drug in preclinical development that acts as a dual antagonist of the prostanoid EP2 and EP4 receptors. It was initially developed by KANAPH Therapeutics and is being investigated primarily for the treatment of solid tumors. The mechanism involves blocking both EP2 and EP4 receptors, which are implicated in tumor growth and immune evasion within the tumor microenvironment. By inhibiting these pathways, KNP-502 aims to enhance anti-tumor immune responses and suppress cancer progression[1].

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER2 (Prostaglandin E2 receptor EP2)

Beyond the preview

Go deeper on KNP-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNP-502.

Explore the full profile